image
Healthcare - Medical - Instruments & Supplies - NYSE - US
$ 201.47
-0.856 %
$ 14.6 B
Market Cap
30.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one WST stock under the worst case scenario is HIDDEN Compared to the current market price of 201 USD, West Pharmaceutical Services, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one WST stock under the base case scenario is HIDDEN Compared to the current market price of 201 USD, West Pharmaceutical Services, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one WST stock under the best case scenario is HIDDEN Compared to the current market price of 201 USD, West Pharmaceutical Services, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart WST

image
$360.0$360.0$340.0$340.0$320.0$320.0$300.0$300.0$280.0$280.0$260.0$260.0$240.0$240.0$220.0$220.0$200.0$200.0$180.0$180.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.89 B REVENUE
-1.92%
570 M OPERATING INCOME
-15.70%
493 M NET INCOME
-16.97%
653 M OPERATING CASH FLOW
-15.85%
-379 M INVESTING CASH FLOW
-2.71%
-623 M FINANCING CASH FLOW
-35.47%
749 M REVENUE
0.25%
160 M OPERATING INCOME
-1.05%
130 M NET INCOME
-4.34%
190 M OPERATING CASH FLOW
5.55%
-105 M INVESTING CASH FLOW
-27.65%
-68.9 M FINANCING CASH FLOW
-6.99%
Balance Sheet West Pharmaceutical Services, Inc.
image
Current Assets 1.54 B
Cash & Short-Term Investments 485 M
Receivables 552 M
Other Current Assets 501 M
Non-Current Assets 2.11 B
Long-Term Investments 202 M
PP&E 1.69 B
Other Non-Current Assets 217 M
13.30 %15.16 %13.75 %5.55 %46.28 %5.96 %Total Assets$3.6b
Current Liabilities 550 M
Accounts Payable 239 M
Short-Term Debt 17.9 M
Other Current Liabilities 293 M
Non-Current Liabilities 411 M
Long-Term Debt 284 M
Other Non-Current Liabilities 126 M
24.90 %30.51 %29.59 %13.14 %Total Liabilities$961.1m
EFFICIENCY
Earnings Waterfall West Pharmaceutical Services, Inc.
image
Revenue 2.89 B
Cost Of Revenue 1.89 B
Gross Profit 998 M
Operating Expenses 429 M
Operating Income 570 M
Other Expenses 77.2 M
Net Income 493 M
3b3b3b3b2b2b2b2b1b1b500m500m003b(2b)999m(429m)570m(77m)493mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
34.51% GROSS MARGIN
34.51%
19.70% OPERATING MARGIN
19.70%
17.03% NET MARGIN
17.03%
18.37% ROE
18.37%
13.52% ROA
13.52%
14.96% ROIC
14.96%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis West Pharmaceutical Services, Inc.
image
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 493 M
Depreciation & Amortization 155 M
Capital Expenditures -377 M
Stock-Based Compensation 18.7 M
Change in Working Capital 2.9 M
Others -16.3 M
Free Cash Flow 276 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets West Pharmaceutical Services, Inc.
image
Wall Street analysts predict an average 1-year price target for WST of $364 , with forecasts ranging from a low of $250 to a high of $536 .
WST Lowest Price Target Wall Street Target
250 USD 24.09%
WST Average Price Target Wall Street Target
364 USD 80.87%
WST Highest Price Target Wall Street Target
536 USD 166.04%
Price
Max Price Target
Min Price Target
Average Price Target
550550500500450450400400350350300300250250200200150150May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.06% DIVIDEND YIELD
0.21 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.900.900.800.800.700.700.600.600.500.500.400.400.300.300.200.200.100.100.000.000.110.120.130.140.150.160.170.180.190.20.210.110.120.130.140.150.160.170.180.190.20.210.110.120.130.140.150.160.170.180.190.20.120.450.130.490.140.530.150.570.160.610.170.650.180.690.190.730.20.770.210.810.422015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership West Pharmaceutical Services, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
218 K USD 1
6-9 MONTHS
9.67 M USD 2
9-12 MONTHS
25 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
West Pharmaceutical Services, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - WST NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 2 weeks ago
ATTENTION WST SHAREHOLDERS: Investors who Lost Money on West Pharmaceutical Services, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 2 weeks ago
West Pharmaceutical Services, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - WST NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 2 weeks ago
Shareholders that Lost Money on West Pharmaceutical Services, Inc. (WST) Should Contact Levi & Korsinsky About Securities Fraud Investigation - WST NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 2 weeks ago
WST ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your West Pharmaceutical Services, Inc. investment NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 2 weeks ago
West Pharmaceutical Services, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - WST NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 3 weeks ago
WST ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your West Pharmaceutical Services, Inc. investment NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 3 weeks ago
West Pharmaceutical Services, Inc. (WST) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 3 weeks ago
West Pharmaceutical Services, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - WST NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 3 weeks ago
Levi & Korsinsky Reminds West Pharmaceutical Services, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - WST NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 3 weeks ago
Levi & Korsinsky Reminds Shareholders of an Investigation into West Pharmaceutical Services, Inc. (WST) Regarding Potential Securities Fraud Allegations NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 4 weeks ago
West Pharmaceutical Services, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - WST NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations. accessnewswire.com - 1 month ago
8. Profile Summary

West Pharmaceutical Services, Inc. WST

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 14.6 B
Dividend Yield 0.06%
Description West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Contact 530 Herman O. West Drive, Exton, PA, 19341-0645 https://www.westpharma.com
IPO Date March 17, 1980
Employees 10600
Officers Mr. Eric M. Green Non-Independent Chair of the Board, President & Chief Executive Officer Ms. Kimberly Banks MacKay Senior Vice President, General Counsel & Company Secretary Mr. John P. Sweeney C.F.A. Head of Investor Relations Mr. Rudy Poussot Senior Vice President of Strategy & Corporate Development Ms. Kathy DePadua Senior Vice President and Chief Quality & Regulatory Officer Mr. Bernard J. Birkett Senior Vice President & Chief Financial Officer Mr. Chad R. Winters Vice President of Finance & Chief Accounting Officer Ms. Annette F. Favorite Chief Human Resources Officer & Senior Vice President Ms. Aileen Ruff-Patry President of Contract Manufacturing Michele Polinsky Vice President of Global Communications